Texas A&M University-Corpus Christi, Institutional Biosafety Committee
Meeting Minutes
Meeting Date: 06/26/2026 **Meeting Time:** 2:00 PM
Meeting Location: [redacted]

Note: The approved meeting minutes will be posted publicly per the National Institutes of Health (NIH), Office of Science Policy (OSP) requirement NOT-OD-25-082. All information on matters not covered by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules will be redacted as allowed in NOT-OD-25-082.

Call to Order:
The Texas A&M University-Corpus Christi, Institutional Biosafety Committee (IBC) met on 06/26/2026 [redacted].

The quorum required is 4. There were 7 voting members and 1 non-voting members present at the meeting. Quorum was confirmed.

The meeting was called to order at 2:00 PM.

Meeting Attendance:

Meeting Chair: Dr. Patrick Larkin, PhD.

Voting Full Board Members:

Name	Scientific Status	Affiliation Status	Attended by Teleconference?
Patrick Larkin, Ph.D. (Chair)	Scientific, rDNA expert	Affiliated	No
Jeffrey Turner, Ph.D. (Vice Chair)	Scientific, rDNA Expert and Animal Expert	Affiliated	Yes
Harshkumar Bhakta, M.S.	Scientific, EHS	Affiliated	Yes
Jonda Halcomb, Ph.D.	Scientific, Community Member	Non-affiliated	Yes
Yessenia Morris, B.S.	Scientific, Community Member and Animal Expert	Non-affiliated	Yes
Lee Lehman, M.S.	Scientific, Plant Expert	Affiliated	No
Boram Lim, Ph.D.	Scientific, Kinesiology	Affiliated	Yes

Voting Alternate Members: None.

Non-voting Members in Attendance:

Name	Scientific Status	Affiliation Status	Attended by Teleconference?
Mary Mantle, R.EEG T, REP T. CMEG	Scientific, Community Member	Non-affiliated	Yes

Members attending by teleconference were confirmed as able to actively participate.

Full Board Members Absent: None.

IBC Staff: John Scarpa, PhD

Guests: None.

I. Conflict of Interest
Members are reminded to disclose any conflict of interest related to any of the items on the agenda. The Chair called for any disclosures of conflict of interest. No conflicts were declared.

II. Minutes
Minutes from the May 29, 2026, meeting were reviewed. It was noted that Mr. Lehman's name as Chair was misspelled (double e in last name) and was corrected.

The Chair invited additional comments, questions, and/or concerns. Hearing none, the motion to approve the corrected meeting minutes was made, seconded, and carried.

Vote Count	Vote Type	Comments
7	For	
0	Against	
0	Abstain	
0	Conflict of Interest	
0	Not present for Vote	

III. Old Business

[redacted]

[redacted]

[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	

IV. New Business
Chair: None.

Education: None.

EHS:

[redacted]

Other:

[redacted]

V. New Studies
None.

VI. Tabled Studies
None.

VII. De Novo Reviews

[redacted]

[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	

[redacted]

Reviewer had no other comments or stipulations. This is a De Novo review. All biohazards are noted and [redacted]

[redacted]

[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	

[redacted]

IBC Number:	**TAMU-CC-IBC-2026-0106**
Protocol Title:	Copy of Bioimaging-based methods for studying the antibacterial mechanism of ionic silver and nanosilver
Principal Investigator:	Pavel, Ioana, PhD
Primary Reviewers:	Jonda Halcomb, PhD
Conflict of Interest:	N/A
Lay Summary:	The main goal of this research is to develop bioimaging-based methods for studying the antibacterial mechanism of ionic silver (Ag+) and nanosilver such as silver nanoparticles (AgNPs). It is important to study these mechanisms for several reasons: 1. Bioimaging allows researchers to visualize the interaction and localization of silver ions and nanoparticles within bacterial cells or on bacterial surfaces. This helps to understand how silver species interact with bacterial components and where they are located, providing insights into their mechanisms of action. 2. Bioimaging can reveal the specific sites and processes targeted by silver species within bacterial cells. For example, it can help determine whether silver disrupts cell membranes, interferes with intracellular processes, or affects specific organelles. This information is crucial for understanding the underlying antibacterial mechanisms and designing effective antibacterial agents. 3. Bioimaging enables real-time monitoring of the antibacterial process. Researchers can track changes in bacterial morphology, viability, and behavior over time in response to silver treatment. This dynamic information is valuable for elucidating the kinetics and dynamics of antibacterial activity. 4. Bioimaging-based methods can help quantify the extent of silver uptake by bacterial cells, human cells, and tissues. This information is essential for determining optimal dosages that effectively inhibit bacterial growth without causing excessive toxicity to human cells or the environment. 5. Bioimaging can shed light on how bacteria develop resistance to silver species. By visualizing the interactions between silver and bacterial cells, researchers can identify potential mechanisms of resistance.
Biohazardous Agents:	Bacteria, Human cell lines, human blood, and BL21(DE3)pLysS competent cells.
NIH Guidelines:	II-A-3: Use of human cells/cell lines or tissues (e.g. human blood, 293 cell lines, CSF), III-E, III-F: Generation or use of cDNA/genomic libraries, III-F: Use of recombinant or synthetic nucleic acid molecules for detection (e.g. probes)
Submission Type:	Research Protocol
Biosafety Level:	BSL-2

There are several items (e.g., missing OHP enrollment, incorrect protocol numbers) that need correction. Reviewer noted that in one procedural entry it notes aerosols may be generated by stock culture opening, but not noted in another entgry. In that section it does refer to the other entry, which is acceptable. Committee was unsure if NIH II-A-3 needs to be checked. Post-meeting it was determined that Dr. Pavel is working with a human cell line that is covered (i.e., HEK 293).

The Chair invited additional comments, questions, and/or concerns. Having none, the motion to approve with stipulations with a permit expiration date of three (3) years and annual review was made, seconded, and carried. The requested changes will be reviewed by the Chair.

Vote Count	Vote Type	Comments
7	For	
0	Against	
0	Abstain	
0	Conflict of Interest	
0	Not present for Vote	

Stipulations:
1. Section 9.0 (Related Studies): Need to correct "Notes" as 2026-0105 is Dr. Omoruyi's new protocol and both the old and new should be available in drop down menu. Also, remove comment about "as suggested".
2. Section 11.2 (Add all procedures or experiments involving biohazards): No entries were noted as using Human Cell Lines or Human Blood. Please add in new entries for procedures for these biohazards or modify existing entries where human cell line, human blood, or both are used.
3. Update protocol numbers
4. Delete, as Dr. Sparks is no longer a faculty member.
5. Update protocol number here, and throughout manual for other protocol numbers that have changed.
6. Update protocol number.



[redacted]

[redacted]

[redacted]

[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	

[redacted]

[redacted]

[redacted]

[redacted]

[redacted]

[redacted]

[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	
[redacted]	[redacted]	
[redacted]	[redacted]	

[redacted]

VIII. Annual Reviews
None.

IX. Amendments

[redacted]

Ms. Mantle departs 2:36 PM. (No change in quorum)

X. Reportable Events
None.

XI. Lab Inspections
None.

XII. Biological Safety (BSR) or Chair Review
None.

XIII. Miscellaneous
[redacted]

XIV. Closing Comments
[redacted]

The meeting was adjourned at 2:42 PM.